Hematopoietic Stem Cell Transplantation for Systemic Sclerosis. Maria Carolina de Oliveira Ribeirão Preto Medical School University of São Paulo 2018

Similar documents
Our place in the World

Having a stem cell transplant for scleroderma a patient and doctor perspective

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates

NOT COPY. Choice of the primary outcome: Pro Lung 03/09/2018. Lung assessment in clinical trials

BSR and BHPR guideline for the treatment of systemic sclerosis

Emerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow

Immunotherapies for aplastic anemia

Hematopoietic Cell Transplantation for Autoimmune Diseases

Understanding Myositis Medications

Bone Marrow Transplantation in Neurological Disease

Related Policies None

Scleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas

Stem cell therapy for diabetes mellitus

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Hematopoietic Cell Transplantation for Autoimmune Diseases

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Review. Autologous stem cell transplantation in systemic sclerosis: a systematic review

The use of stem cells for the treatment of autoimmune diseases

Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

Statement of Impact >>>>>

ASTIS trial. The European Group for Blood and Marrow Transplantation

Corporate Medical Policy

Disclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient?

Autologous Hematopoietic Stem Cell Transplantation for Type 1 Diabetes

Evidence from bone marrow transplantation

Hematopoietic Cell Transplantation for Autoimmune Diseases

DocSpot what patients want to know

Stem Cell Transplantation (SCT) in Scleroderma

Supplementary Online Content

Evidence Review: Title. Month/ Year. Evidence Review:

Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?

High-Dose Immunosuppression and Hematopoietic Stem Cell Transplantation in Autoimmune Disease: Clinical Review

Name of Policy: Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases

Disclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data

Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a caseseries

Myositis and Your Lungs

Table e-1: Patient Level Baseline Characteristics

REVIEW. OPEN Bone Marrow Transplantation (2017) 52,

different phenotypes

Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis

SCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston

DEPARTMENT OF RHEUMATOLOGY

Clinical Policy Title: Stem cell transplants for autoimmune disease

Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients with Pulmonary Involvement

UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma.

Immunosuppression for interstitial lung disease in systemic sclerosis

TYPE 1 DIABETES MELLITUS (DM)

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Annual Rheumatology & Therapeutics Review for Organizations & Societies

DRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)

Ayano et al. Arthritis Research & Therapy (2019) 21:30

Haploidentical Transplantation today: and the alternatives

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin

Summary of Evidence-based Clinical Practice Guidelines for Care of Patients with Oral and Gastrointestinal Mucositis (2005 Update) ORAL MUCOSITIS

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

SCLERODERMA SPECTRUM DISEASE

47 studies found for: systemic lupus erythematosus AND mycophenolic acid

Treatment of Scleroderma Informed by Canadian Research

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Immunogenetics in sickle cell disease. Karina Tozatto Maio 2018 USP-USPC Workshop on Hematology and Bone Marrow Transplant 11/05/2018

Echo in Systemic Disease

Hematopoietic Cell Transplantation for Myelofibrosis. Outline

Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases

Lung Involvement In Systemic Sclerosis. Milind Y Nadkar, Nayan K Desai INTRODUCTION

ANCA+ VASCULITIDES CYCAZAREM,

Haematopoietic stem cell transplantation is the

diabetes A risky bet against Experimental treatment with chemo-therapy and stem cells frees 14 patients from insulin injections MARCOS PIVETTA

Clinical Commissioning Policy Proposition:

TOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW

High Resolution Mass Spectrometry Lab

systemic sclerosis Author: C hris to p he r P D e nto n A ABSTRACT Introduction Current paradigm for SSc pathogenesis

ACCUMULATED CLINICAL EXPErience

An Overview of Blood and Marrow Transplantation

High Impact Rheumatology

What will we discuss today?

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Committee Approval Date: May 9, 2014 Next Review Date: May 2015

Benlysta (belimumab) Prior Authorization Criteria Program Summary

Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research

Aplastic Anemia: Understanding your Disease and Treatment Options

Interstitial Inflammation

SCLERODERMA. Scleroderma update. No disclosures or conflicts. Leslie Kahl, M.D. April 10, 2015

Lines and crackles. Making sense of ILD

Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome

Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS

The relationship between PML-rituximab and other immunobiologicals: an overview

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Interstitial Lung Disease

Number: 0606 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB.

Transcription:

Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Maria Carolina de Oliveira Ribeirão Preto Medical School University of São Paulo 2018

LOCALIZED SCLERODERMA Restricted to the skin Benign Aesthetic implications SYSTEMIC SCLEROSIS Physical Limitations Poor quality of life Mortality

Vasculopathy Fibrosis Inflammation

Allanore et al. Nature Disease Primers 2015

Conventional Treatment Skin Methotrexate Cyclophosphamide Mycophenolate mofetil Interstitial lung Cyclophosphamide MMF GI tract Omeprazol Kidneys ACE inhibitors PAH Sidenafil Bosentan Under investigation Rituximab Tocilizumab Riociguat Nintendanib Fresolimumab

Despite advances in disease management, mortality of severe systemic sclerosis patients has not changed in the last 40 years. Elhai et al. Rheumatology 2012

Autologous Hematopoietic Stem Cell Transplantation Mobilization Cyclophosphamide 2-4g/m2 G-CSF Graft selection? Transplantation Cyclophosphamide 200mg/kg rabbit ATG G-CSF

Autologous Hematopoietic Stem Cell Transplantation INDICATIONS Diffuse skin involvement with worsening of the Rodnan s skin score in the past 6 months or Interstitial lung involvement with FVC or DLCO worsening >10% in 6 m

Autologous Hematopoietic Stem Cell Transplantation SKIN INVOLVEMENT Rodnan s score X time (years after AHSCT) 0 1 2 3 4 5 Sullivan et al, BBMT 2010 Burt and Oliveira et al, Lancet 2013

Autologous Hematopoietic Stem Cell Transplantation 20! m PRE-TRANSPLANT 6 MONTHS 20! m SKIN INVOLVEMENT Forearm biopsies 20! m C 20! m 20! m 20! m 12 MONTHS D 50 25 C 100! m 100! m 100! m 100! m 100! m 100! m Collagen change (% of Picrosirius Red staining) D 0 50 25 0-25 -50 * * -75-25 -100-50 Baseline 6 months 1 year -75-100 Baseline 6 months 1 year Arruda LCM, Tese de Doutorado FMRP-USP, 2017

Autologous Hematopoietic Stem Cell Transplantation FVC LUNG INVOLVEMENT Pulmonary function tests DLCO Burt and Oliveira et al, Lancet 2013

AHSCT: randomized studies ASSIST: Autologous systemic sclerosis immune suppression trial Burt et al. Lancet 2011

AHSCT: randomized studies ASSIST: Autologous systemic sclerosis immune suppression trial Burt et al. Lancet 2011

AHSCT: randomized studies ASSIST: Autologous systemic sclerosis immune suppression trial Rodnan s score Forced Vital Capacity Burt et al. Lancet 2011

AHSCT: randomized studies ASTIS: Autologous stem cell transplantation vs immunosuppression van Laar et al. JAMA 2014

AHSCT: randomized studies ASTIS: Autologous stem cell transplantation vs immunosuppression van Laar et al. JAMA 2014

AHSCT: randomized studies SCOT: Scleroderma cyclophosphamide or transplantation Sullivan et al. NEJM 2018

AHSCT: randomized studies SCOT: Scleroderma cyclophosphamide or transplantation Sullivan et al. NEJM 2018

Kowal-Bielecka et al. Ann Rheum Dis 2017

What have we learned over the past 20 years??

Global survival per disease, after AHSCT RHEUMATOID ARTHRITIS MULTIPLE SCLEROSIS IDIOPATHIC JUVENILE ARTHRITIS SLE SYSTEMIC SCLEROSIS HEMATOLOGIC CYTOPENIAS SYSTEMIC SCLEROSIS Farge et al. Haematologica 2010

What have we learned over the past 20 years?? Patient selection - do not include advanced disease patients

What have we learned over the past 20 years?? Patient selection - do not include advanced disease patients Cardiac screening

90 transplanted patients Mortality of 6% (5 patients) 4 cardiac-related deaths Constrictive pericarditis (1) Right ventricle dysfunction (2) Left ventricle dysfunction (1) Burt, Oliveira et al. Lancet 2013

Pre-AHSCT Cardiac Screening Echocardiography Holter (24h EKG) Heart MRI Right sided heart catheterization Farge et al. Bone Marrow Transplant 2017

What have we learned over the past 20 years?? Patient selection - do not include advanced disease patients Cardiac screening Graft manipulation?

CD34+ graft selection p=0.41 p=0.05 p=0.04 Oliveira, Labopin et al. Bone Marrow Transplant 2016

What have we learned over the past 20 years?? Patient selection - do not include advanced disease patients Cardiac screening Graft manipulation? Effects on vasculopathy? Effects on gastrointestinal tract

Equipe Clínica Hemocentro e Centro de Terapia Celular Daniela Moraes Karla Costa Pereira Kelen Malmegrim Dimas Tadeu Covas, Juliana Elias Vanessa Leopoldo Júlia Teixeira de Azevedo, Maristela Delgado Orellana Ana Beatriz Stracieri Andreia Zombrilli Gislane Vilela, Simone Kashima, Fabiano Pieroni Marília Cirioli João Rodrigues Lima Jr Patrícia Palma Renato Cunha Ana Luísa Guimarães Marianna Vasconcelos Marco Antônio Zago, Thalita Costa Maynara Santana Gil de Santis Belinda Simões Benedito Prado Maria Carolina de Oliveira Júlio César Voltarelli (in memoriam)